Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T38846 |
Vevorisertib trihydrochloride
ARQ 751 trihydrochloride |
Akt | Cytoskeletal Signaling; PI3K/Akt/mTOR signaling |
Vevorisertib trihydrochloride(ARQ 751 trihydrochloride) 是一种具有选择性和有效性的 pan-AKT 和 AKT1-E17K 突变抑制剂,抑制 AKT1 、AKT2 和 AKT3 。 Vevorisertib trihydrochloride 可用于研究肝癌和晚期实体瘤。 | |||
T38847 |
Vevorisertib
Vevorisertib,ARQ 751 |
Others | Others |
Vevorisertib (ARQ 751) is a highly effective oral compound that selectively inhibits pan-AKT serine/threonine kinases such as AKT1 (with an IC50 value of 0.55 nM), AKT2 (with an IC50 value of 0.81 nM), and AKT3 (with an IC50 value of 1.31 nM). This compound, either as a standalone treatment option or in combination with other anti-cancer agents, is ideally suited for conducting research on solid tumors characterized by PIK3CA/AKT/PTEN mutations[4]. |